Pugatch Consilium managing director, Meir Perez Pugatch, says that IP has been the “bridge” in the various biopharma R&D collaborations that have helped deliver unprecedented results during the pandemic. He also weighs in on the divisive proposal of waiver of intellectual property rights for vaccines, treatments and diagnostics relating to COVID-19.

The US obtained access to doses that it will donate to low- and low-middle-income countries, Merck & Co. is lining up government purchases of its Phase III drug, and Ocugen will submit a BLA in the US rather than pursue an EUA for Bharat's vaccine. Plus progress and setbacks for COVID-19 therapeutics. 

News and views from day one of the BIO Digital annual meeting include debate about when FDA will go back to the offices, industry's role in pandemic-related policy discussions and how to prepare for the next pandemic. 

News and views from day one of the BIO Digital annual meeting include debate about when FDA will go back to the offices, industry's role in pandemic-related policy discussions and how to prepare for the next pandemic.